Windtree Therapeutics, Inc. (NasdaqCM: WINT) recently showcased promising data on istaroxime, an investigational treatment ...

Hypovolemia is ultimately caused by either a loss of blood or a loss of water. In either instance, the depletion of fluid ...

For patients with cardiogenic shock transferring from a referring hospital, the median time to acceptance fell from 1.55 hours to 0.35 hours. The analysis indicated no differences in mortality ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

An important cohort of patients who might be expected to derive maximum benefit from angioplasty comprises patients presenting with MI complicated by cardiogenic shock. However, in the recently ...

Progress in assessing cardiovascular risk and identifying early prevention opportunities, improvements in treating heart failure, new therapies for bleeding strokes, strategies for reducing the ...

Thiazolidinedione use was associated with lower risk for mortality and cardiorenal events among adults with type 2 diabetes and acute kidney disease.

Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, ...